However, subset analyses of phase III trials suggest that patients with EGFR mutation - positive NSCLCs do not benefit from immunotherapy
compared with docetaxel.
Not exact matches
Median overall survival of patients receiving nivolumab was 9.2 months,
compared with six months for patients who received
docetaxel.
Results also showed 27.7 percent of patients in the ADT plus
docetaxel arm had a decline in prostate specific antigen (PSA) to less than 0.2 ng / mL at 12 months
compared with 16.8 percent for those taking ADT alone.
Almost 72 % of
docetaxel patients were current or former smokers,
compared with 81.7 % in the erlotinib group.
A total of 28.9 % of patients receiving
docetaxel had not progressed after 6 months,
compared with 16.9 % of erlotinib patients.
The drug's manufacturer, Roche, said trials in these patients have shown that giving pertuzumab in combination
with the drugs trastuzumab (Herceptin) and
docetaxel could extend survival by nearly 16 months
compared to standard treatment.
For both populations, though, disease prognosis remains poor: the median progression - free survival for
docetaxel - treated patients was 3.4 months,
compared with 2.4 months for erlotinib.